Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.54 |
| ▸ | SLC16A1 | P53985 | 5/20 | 0.54 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3826419 | 0.87 | SLC16A1 (0.72) | CYP3A4CYP2C9SLC16A1SLC16A3ADORA2B | |
| SCHEMBL3827907 | 0.78 | SLC16A1 (0.80) | CYP3A4CYP2C9SLC16A1SLC16A3 | |
| SCHEMBL3827911 | 0.78 | SLC16A1 (0.80) | CYP3A4CYP2C9SLC16A1SLC16A3 | |
| SCHEMBL4840916 | 0.72 | SLC16A1 (0.51) | CYP3A4CYP2C9SLC16A1SLC16A3 | |
| SCHEMBL23958362 | 0.70 | SLC16A1 (1.00) | CYP3A4CYP2C9SLC16A1SLC16A3 | |
| SCHEMBL3826454 | 0.70 | SLC16A1 (1.00) | CYP3A4CYP2C9SLC16A1SLC16A3 | |
| SCHEMBL3826451 | 0.70 | SLC16A1 (1.00) | CYP3A4CYP2C9SLC16A1SLC16A3 | |
| SCHEMBL3828105 | 0.70 | SLC16A1 (0.82) | CYP3A4CYP2C9SLC16A1SLC16A3 | |
| SCHEMBL3828110 | 0.70 | SLC16A1 (0.82) | CYP3A4CYP2C9SLC16A1SLC16A3 | |
| SCHEMBL3827786 | 0.70 | SLC16A1 (0.74) | CYP3A4CYP2C9SLC16A1SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414825-B9 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2009-09-16 | — | — | EP | disclosed |